• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Coverage

Latest content

Michael Friis

Head of Equities

Michael Friis portrait

Coverage

HydractAudientesRealfictionShape RoboticsScape TechnologiesGreenMobilityCurasightOrderYOYOPenneoPhotocatOdicoAgillicBawat Water TechnologiesImperoMapsPeopleNNITNordic SolarScandinavian Medical SolutionsWindowMaster InternationalGomSpaceCABA CapitalAscelia PharmaEmbla MedicalBioPortoGubraExpreS2ion Biotech

Latest content

ShowingAll content types

Gubra: UCN2 enters the clinic with an ambitious Phase 1/2a design and an R&D Day date

Analyst Comment 28.07.2026 klo 09.50 by Michael Friis
Gubra

Gubra: Boehringer Ingelheim initiates Phase 2 of triple agonist, triggering EUR 10m milestone

Analyst Comment 16.07.2026 klo 08.49 by Michael Friis
Gubra

Ascelia Pharma: Market is pricing the downside, but the CRL letter and management commentary still support better scenarios

Analyst Comment 15.07.2026 klo 09.03 by Michael Friis
Ascelia Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account

Ascelia Pharma: Published FDA letter raises the odds of a more demanding path for Orviglance

Analyst Comment 14.07.2026 klo 09.20 by Michael Friis
Ascelia Pharma

GreenMobility (Investment case): H1 2026, profitability and cash returns proven, H2 to restore the growth trajectory

Research 13.07.2026 klo 14.00 by Michael Friis, Victor Skriver
GreenMobility

Ascelia Pharma: Update on Orviglance NDA suggests clinical CRL concerns center on image reading

Analyst Comment 13.07.2026 klo 08.45 by Michael Friis
Ascelia Pharma

GreenMobility: Presentation H1 2026 results (Recording)

Analyst Comment 10.07.2026 klo 15.27 by Michael Friis
GreenMobility

GomSpace – Management Q&A (Recording)

Analyst Comment 10.07.2026 klo 15.18 by Michael Friis
GomSpace

GreenMobility: H1-2026 Full report confirms preliminary figures, balance sheet and cash flow underline earnings quality

Analyst Comment 09.07.2026 klo 09.00 by Michael Friis
GreenMobility

GreenMobility: Lowers revenue guidance but keeps EBITDA growth intact

Analyst Comment 07.07.2026 klo 08.48 by Michael Friis
GreenMobility